

Appendix 17 - DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Approved settings/ treatment line

Protocols	Drugs in abbreviation	Evidence level
Primary mediastinal LBCL 1st line		
EPOCH-R 6 cycles.	Cyclophosphamide, etoposide, vincristine, doxorubicin, Prednisone	Category 2A, Preferred
RCHOP 6 cycles + RT	rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, radiation therapy	Category 2A
RCHOP 4 cycles then ICE 3 cycles ± Rituximab ± RT	rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, Ifosfamide, carboplatin, etoposideradiation therapy	Category 2B
Primary mediastinal LBCL 2nd line		
Pembrolizumab		Category 2A
Nivolumab ± Brentuximab-Vedotin		Category 2B
CNS Prophylaxis		
Intrathecal Methotrexate and/or cytarabine		Category 2A
Systemic Methotrexate		Category 2A
DLBCL 1st line		
RCHOP	rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.	Category 2A, Preferred
EPOCH-R	Cyclophosphamide, etoposide, vincristine, doxorubicin, Prednisone	Category 2A
DLBCL 1st line, Poor left ventricular function		
R-CEOP	rituximab, cyclophosphamide, etoposide, vincristine, prednisone.	Category 2A
RCDOP	rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, prednisone	Category 2A
DA-EPOCH-R	Etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, rituximab	Category 2A
RGCVP	rituximab, gemcitabine, cyclophosphamide, vincristine, prednisone	Category 2A
DLBCL 1st line, vey Frail Patients > 80 years		
RCDOP	rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, prednisone	Category 2A
RGCVP	rituximab, gemcitabine, cyclophosphamide, vincristine, prednisone	Category 2A
R-mini CHOP	rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.	Category 2A
2nd line, Transplant Candidate		
DHAP ± Rituximab	Dexamethasone, cytarabine, cisplatin	Category 2A, Preferred
DHAX ± Rituximab	Dexamethasone, cytarabine, oxaliplatin	Category 2A, Preferred

GDP ± Rituximab	Gemcitabine, dexamethasone, cisplatin	Category 2A, Preferred
ICE ± Rituximab	Ifosfamide, etoposide, carboplatin	Category 2A, Preferred
ESHAP ± Rituximab	Etoposide, methyl prednisolone, cytarabine, cisplatin	Category 2A

Protocols	Drugs in abbreviation	Evidence level
2nd line, Transplant Candidate		
Gem-Ox ± Rituximab	Gemcitabine, oxaliplatin	Category 2A
MINE ± Rituximab	Mitoxantrone, ifosfamide, etoposide, MESNA	Category 2A
Gem-Ox ± Rituximab	Gemcitabine, oxaliplatin	Category 2A, Preferred
CEOP ± Rituximab	rituximab, cyclophosphamide, etoposide, vincristine, prednisone.	Category 2A
DA-EPOCH ± Rituximab	Etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, rituximab	Category 2A
GDP ± Rituximab	Gemcitabine, dexamethasone, cisplatin	Category 2A
Rituximab		Category 2A
Brentuximab-Vedotin.		Category 2A, CD30 +ve disease
Bendamustine ± Rituximab		Category 2B
Ibrutinib.		Category 2A, non-GCB
Lenalidomide ± Rituximab		Category 2A, non-GCB
DLBCL, Double/ triple Hit		
DA-EPOCH-R	Etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, rituximab	Category 2A, Preferred
R-Hyper CVAD	cyclophosphamide, vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA	Category 2A
R-CODOX-M/ R-IVAC	Cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin, cytarabine, rituximab, ifosfamide, etoposide, MESNA	Category 2A
High Grade BCL		
RCHOP	rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.	Category 2A, Preferred
R-Hyper CVAD	cyclophosphamide, vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA	Category 2A
R-CODOX-M/ R-IVAC	Cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin, cytarabine, rituximab, ifosfamide, etoposide, MESNA	Category 2A